Cardiovascular sequelae of trastuzumab and anthracycline in long-term survivors of breast cancer
Authors' conclusion
The presence of asymptomatic LVSD, abnormal cardiac biomarkers and cardiac risk factors in participants treated with trastuzumab and anthracycline at least 5 years previously is common, even in those with normal LVEF on completion of treatment.
Study context
- Population
- Long-term survivors of HER2-positive breast cancer with normal left ventricular ejection fraction (LVEF) before and on completion of trastuzumab±anthracycline ≥5 years previously
- Participants
- 40 survivors
- Outcome
- Prevalence of CV risk factors, overt CVD and cardiac magnetic resonance (CMR) abnormalities
- Follow-up
- ≥5 years after trastuzumab completion
Methodological detailsRecruited 15 March 2021 to 19 July 2022, Median time since trastuzumab completion 7.8 years (range 5.9-10.8 years); 90% received prior anthracycline
- Recruited 15 March 2021 to 19 July 2022
- Median time since trastuzumab completion 7.8 years (range 5.9-10.8 years); 90% received prior anthracycline
Main finding
As reported in the abstract
- LV systolic dysfunction (LVEF <50%)
- 25%
- Median LVEF (Q1-Q3, 51.3-61.2)
- 55.2%
- NT-proBNP >125 pg/mL
- 30%
- High-sensitivity cardiac troponin T >14 ng/L
- 8%
- New finding of hypertension
- 33%
- Total cholesterol >5.0 mmol/L
- 58%
- Triglycerides >1.7 mmol/L
- 43%
- New diagnosis of DM
- 5%
Observational data: associations, not effects.
Original publication
Cardiovascular sequelae of trastuzumab and anthracycline in long-term survivors of breast cancer. Heart. Published 16 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →